NT
The startup develops anti-miRNA therapies aimed at treating neurological disorders, specifically targeting the underlying mechanisms of epilepsy. By providing transformative disease modification, the company enables healthcare professionals to offer more effective treatment options for patients suffering from this condition.
Updated 2 months ago
Funding
$22.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICFunding rounds are not available yet.
Founders
Product
Features
- The startup develops anti-miRNA therapies aimed at treating neurological disorders, specifically targeting the underlying mechanisms of epilepsy. By providing transformative disease modification, the company enables healthcare professionals to offer more effective treatment options for patients suffering from this condition.